Senate Bill No. 1324 authorizes emergency medical services (EMS) personnel to administer glucagon nasal powder, a medication used to treat severe hypoglycemia in individuals with diabetes. The bill defines "EMS personnel" to include certified emergency medical responders, various classes of certified emergency medical technicians (EMTs), including advanced EMTs, and licensed paramedics. To administer glucagon nasal powder, EMS personnel must be trained according to national standards recognized by the Commissioner of Public Health and must determine that the administration of the medication is necessary for the patient's treatment. The bill mandates that all EMS personnel receive this training from an organization designated by the Commissioner.

Additionally, the bill allows licensed or certified ambulances to be equipped with glucagon nasal powder for administration by trained EMS personnel. The implementation of this bill may incur potential costs for the University of Connecticut, UConn Health, and various municipalities, primarily due to the acquisition of glucagon nasal powder and the required training for EMS personnel. The glucagon nasal powder is estimated to cost approximately $300 per unit, and the overall fiscal impact will depend on the usage rate of the medication and the ability to incorporate the training into existing EMS curricula without significantly increasing costs.